Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Journal of Clinical Medicine|May 13, 2023
Risk-Benefit of IBD Drugs: A Physicians and Patients SurveyFerdinando D'Amico, Sophie Vieujean, Benedicte Caron, et al.Clinical Nutrition ESPEN|December 11, 2024
Exclusion diet and fasting practices in patients with inflammatory bowel disease: Impact on nutritional statusDidier Quilliot, Olivier Bonsack, Meliha Mahmutovic, et al.Therapeutic Advances in Gastroenterology|August 5, 2026
Pulmonary diffusion abnormalities in patients with inflammatory bowel disease: A longitudinal studyHugo Maisonneuve, Benedicte Caron, Anne Guillaumot, et al.Journal of Clinical Medicine|February 11, 2023
iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative ColitisFerdinando D'Amico, Fernando Magro, Benedicte Caron, et al.Inflammatory Bowel Diseases|August 7, 2023
Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert ConsensusFerdinando D'Amico, Fernando Magro, Britta Siegmund, et al.Alimentary Pharmacology & Therapeutics|August 17, 2023
Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitisAchuthan Aruljothy, Siddharth Singh, Neeraj Narula, et al.Journal of Crohn'S & Colitis|May 7, 2019
Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort StudyBenedicte Caron, Laurent Peyrin-Biroulet, Benjamin Pariente, et al.Alimentary Pharmacology & Therapeutics|December 19, 2022
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort studyMathurin Fumery, Antoine Defrance, Xavier Roblin, et al.Journal of Crohn'S & Colitis|September 10, 2025
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAIDPauline Wils, Romain Altwegg, Anthony Buisson, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2024
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID StudyMathurin Fumery, Benedicte Caron, Xavier Hébuterne, et al.Pageof 2